Clinical Trial

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

Active, Not Recruiting Phase 1

Record status

This record was last updated April 6, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Summary

This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist. Study details include: * The study will last up to 2 years after the TIL infusion (Day 0) for each person. * The treatment will last up to 10 days for each person. * Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2024-08-19; most recent amendment 2026-03-31.

Status change: Recruiting → Active, Not Recruiting 2026-03-31

Trial Details

NCT Number	NCT06566092
Lead Sponsor	Iovance Biotherapeutics, Inc.
Conditions	Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma, Melanoma, Rhabdomyosarcoma, Ewing Sarcoma
Enrollment	40 participants
Start Date	2024-03-28
Primary Completion	2026-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-06